NEW YORK, June 3, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. (“Protalix” or the “Company”) (NYSE: PLX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980….